Autolus climbs on collaboration with BioNTech to develop CAR-T cell therapies

Autolus Therapeutics

08/02/2024 11:26

** Shares of Autolus Therapeutics  AUTL.O  rise ~1.3% to
$6.40 premarket
    ** Autolus says collaborating with BioNTech  22UAy.DE  to
develop CAR-T cell therapy program
    ** BioNTech to invest $200 mln in the company
    ** BioNTech to support launch, expansion of development
program of Autolus' lead cell therapy candidate obe-cel and will
receive a royalty on net sales
    ** BioNTech can use Autolus' manufacturing to accelerate
development of BNT211, a cell therapy for solid tumors
    ** Up to last close, stock up more than triple in the last
12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))